Xilio Therapeutics Set for Key Presentations on Immuno-Oncology
Xilio Therapeutics Set for Key Presentations at SITC
Xilio Therapeutics, Inc. (NASDAQ: XLO), a pioneering clinical-stage biotechnology company focused on developing immuno-oncology therapies, is excited to announce a series of poster presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting. This prestigious event will be held over several days, showcasing cutting-edge research and developments in cancer treatments.
Innovative Therapies on Display
At the upcoming SITC meeting, Xilio plans to present significant clinical data regarding its innovative therapeutic candidates, vilastobart and efarindodekin alfa (XTX301). Vilastobart is a breakthrough tumor-activated anti-CTLA-4 therapy, while XTX301 acts as a tumor-activated IL-12, each representing a novel approach to enhancing patient outcomes.
Poster Presentation Highlights
Xilio's poster presentations will provide insights into some promising developments. Here are the details you will not want to miss:
1. ctDNA Biomarker Study
Title: ctDNA as a Potential Surrogate Biomarker for Response to Combination Vilastobart and Atezolizumab in Heavily Pretreated Microsatellite Stable Metastatic Colorectal Cancer
Abstract Number: 541
Presentation Date: Friday, Nov. 7
Poster Hall Hours: 9:00 a.m. to 7:00 p.m. EST
Location: Gaylord Exhibit Halls A & B1
2. XTX301 Pharmacology Findings
Title: XTX301, a Tumor-Activated Interleukin-12, Demonstrated IL-12 Pharmacology in Patients with Advanced Solid Tumors: Pharmacodynamic Data from First-in-Human Phase 1 Study
Abstract Number: 567
Presentation Date: Friday, Nov. 7
Poster Hall Hours: 9:00 a.m. to 7:00 p.m. EST
Location: Gaylord Exhibit Halls A & B1
3. Masked T Cell Engagers Overview
Title: Masked T Cell Engagers Designed to Drive Potent Synthetic Anti-Tumor Immunity with Favorable Tolerability
Abstract Number: 972
Presentation Date: Saturday, Nov. 8
Poster Hall Hours: 9:00 a.m. to 8:40 p.m. EST
Location: Gaylord Exhibit Halls A & B1
About Xilio Therapeutics
Xilio Therapeutics is at the forefront of developing tumor-activated immuno-oncology therapies, striving to improve the lives of individuals battling cancer. The company's proprietary platform enables the advancement of a pipeline of innovative molecules designed to target tumors effectively while minimizing systemic side effects.
The goal of Xilio is clear: to significantly enhance outcomes for cancer patients through novel treatment methodologies that localize therapeutic action within the tumor microenvironment. By focusing on this area, Xilio hopes to redefine how immuno-oncology treatments are developed and delivered.
Investor and Media Contacts
If you are interested in learning more about Xilio Therapeutics or attending the SITC presentations, please reach out:
Investor Contact:
investors@xiliotx.com
Media Contact:
Josie Butler
josie@1abmedia.com
Frequently Asked Questions
What is the significance of the SITC Annual Meeting?
The SITC Annual Meeting is a pivotal event where the latest advancements in cancer immunotherapy are shared among leading experts in the field.
What is Xilio's focus in cancer therapy?
Xilio focuses on developing tumor-activated immuno-oncology therapies aimed at improving treatment efficacy and reducing systemic side effects for cancer patients.
How does XTX301 function?
XTX301 is designed to activate IL-12 specifically within tumor tissues, enhancing anti-tumor immune responses while minimizing toxicity.
When will the posters be presented?
The poster presentations will take place on November 7 and 8 at the SITC 40th Annual Meeting.
How can I contact Xilio for more information?
You can reach Xilio's investor relations at investors@xiliotx.com or media inquiries at josie@1abmedia.com.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
